Understanding the mechanisms of action of methotrexate: Implications for the treatment of rheumatoid arthritis

Bulletin of the NYU Hospital for Joint Diseases

Volumn 65, Issue 3, 2007, Pages 168-173

  Tian, Henghe ^a   Cronstein, Bruce N ^a,b,c  

^a NEW YORK UNIVERSITY MEDICAL CENTER   (United States)

^b NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c Division of Clinical Pharmacology

Author keywords

[No Author keywords available]

Indexed keywords

5 AMINO 4 IMIDAZOLECARBOXAMIDE RIBOSIDE; 5,10 METHYLENETETRAHYDROFOLATE REDUCTASE (FADH2); 7 HYDROXYMETHOTREXATE; ADENOSINE; ADENOSINE RECEPTOR; ADENOSINE RECEPTOR BLOCKING AGENT; ALPHA,BETA METHYLENEADENOSINE DIPHOSPHATE; ANTIRHEUMATIC AGENT; CAFFEINE; DISEASE MODIFYING ANTIRHEUMATIC DRUG; FOLIC ACID; FOLINIC ACID; METHOTREXATE; THEOPHYLLINE;

ANEMIA; ANTIINFLAMMATORY ACTIVITY; BONE MARROW SUPPRESSION; BONE MARROW TOXICITY; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; DRUG ANTAGONISM; DRUG EFFICACY; DRUG MECHANISM; DRUG MEGADOSE; DRUG METABOLISM; FATIGUE; HUMAN; KIDNEY FAILURE; LETHARGY; LIVER FIBROSIS; LIVER TOXICITY; LOW DRUG DOSE; LUNG FIBROSIS; MOUTH ULCER; NAUSEA; NEOPLASM; NEUTROPENIA; NONHUMAN; PHARMACOGENETICS; PURINE SYNTHESIS; PYRIMIDINE SYNTHESIS; REVIEW; RHEUMATOID ARTHRITIS; SINGLE NUCLEOTIDE POLYMORPHISM; STOMATITIS; SUBCUTANEOUS NODULE; UNSPECIFIED SIDE EFFECT; DRUG INTERACTION; GENETICS; METABOLISM;

ADENOSINE; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; DRUG INTERACTIONS; HUMANS; METHOTREXATE; PHARMACOGENETICS;

EID: 38449094689     PISSN: 19369719     EISSN: 19369727     Source Type: Journal    
DOI: None     Document Type: Review

References (23)

1. Weinblatt ME, Coblyn JS, Fox DA, et al. Efficacy of low-dose methotrexate in rheumatoid arthritis. N Engl J Med. 1885;312:818-22.
2. Cronstein BN. Low-dose methotrexate: a mainstay in the treatment of rheumatoid arthritis. Pharmacol Rev. 2005 Jun;57(2):163-72.
3. Swierkot J, Szechinski J. Methotrexate in rheumatoid arthritis. Pharmacol Rep. 2006 Jul-Aug;58(4):473-92.
4. Chan ES and Cronstein BN. Molecular action of methotrexate in inflammatory diseases. Arthritis Res. 2002 Mar;4(4):266-73.
5. Cronstein BN, Naime D, Ostad E. The antiinflammatory mechanism of methotrexate: increased adenosine release at inflamed sites diminishes leukocyte accumulation in an in vivo model of inflammation. J Clin Investig. 1993 Dec;92:2675-82.
6. Morabito L, Montesinos MC, Schreibman DM, et al. Methotrexate and sulfasalazine promote adenosine release by a mechanism that requires ecto-5′-nucleotidase-mediated conversion of adenine nucleotides. J Clin Invest. 1998 Jan;101(2):295-300.
7. Montesinos MC, Takedachi M, Thompson LF, et al. The antiinflammatory mechanism of methotrexate depends on extracellular conversion of adenine nucleotides to adenosine by ecto-5′-nucleotidase: findings in a study of ecto-5′-nucleotidase gene-deficient mice. Arthritis Rheum. 2007 May;56(5):1440-5.
8. Riksen NP, Barrera P, van den Broek PH, et al. Methotrexate modulates the kinetics of adenosine in humans in vivo. Ann Rheum Dis. 2006 Apr;65(4):465-70.
9. Cronstein BN, Eberle MA, Gruber HE, Levin RI. Methotrexate inhibits neutrophil function by stimulating adenosine release from connective tissue cells. Proc Natl Acad Sci U S A. 1991 Mar;88(6):2441-5.
10. Bours MJ, Swennen EL, Di Virgilio F, et al. Adenosine 5′-triphosphate and adenosine as endogenous signaling molecules in immunity and inflammation. Pharmacol Ther. 2006 Nov;112(2):358-404.
11. Montesinos MC, Desai A, Delano D, et al. Adenosine A2A or A3 receptors are required for inhibition of inflammation by methotrexate and its analog MX-68. Arthritis Rheum. 2003 Jan;48(1):240-7.
12. Montesinos MC, Yap JS, Desai A, et al. Reversal of the antiinflammatory effects of methotrexate by the nonselective adenosine receptor antagonists theophylline and caffeine: evidence that the antiinflammatory effects of methotrexate are mediated via multiple adenosine receptors in rat adjuvant arthritis. Arthritis Rheum. 2000 Mar;43(3):656-63.
13. Silke C, Murphy MS, Buckley T, et al. The effects of caffeine ingestion on the efficacy of methotrexate. Rheumatology. 2000 (Oxford);40(Suppl 1):34.
14. Nesher G, Mates M, Zevin S. Effect of caffeine consumption on efficacy of methotrexate in rheumatoid arthritis. Arthritis Rheum. 2003 Feb;48(2):571-2.
15. Benito-Garcia E, Heller JE, Chibnik LB, et al. Dietary caffeine intake does not affect methotrexate efficacy in patients with rheumatoid arthritis. J Rheumatol. 2006 Jul;33(7):1275-81.
16. Cronstein BN. Pharmacogenetics in the rheumatic diseases. Bull NYU Hosp Jt Dis. 2006;64(1-2):16-9.
17. Dervieux T, Kremer J, Lein DO, et al. Contribution of common polymorphisms in reduced folate carrier and gamma-glutamylhydrolase to methotrexate polyglutamate levels in patients with rheumatoid arthritis. Pharmacogenetics. 2004 Nov;14(11):733-9.
18. Wessels JA, Kooloos WM, De Jonge R, et al. Relationship between genetic variants in the adenosine pathway and outcome of methotrexate treatment in patients with recent-onset rheumatoid arthritis. Arthritis Rheum. 2006 Sep;54(9):2830-9.
19. Wessels JA, van der Kooij SM, le Cessie S, et al. Pharmacogenetics Collaborative Research Group. A clinical pharmacogenetic model to predict the efficacy of methotrexate monotherapy in recent-onset rheumatoid arthritis. Arthritis Rheum. 2007 Jun;56(6):1765-75.
20. Merrill JT, Shen C, Schreibman D, et al. Adenosine A1 receptor promotion of multinucleated giant cell formation by human monocytes: a mechanism for methotrexate-induced nodulosis in rheumatoid arthritis. Arthritis Rheum. 1997 Jul;40(7):1308-15.
21. Chan ES, Montesinos MC, Fernandez P, et al. Adenosine A(2A) receptors play a role in the pathogenesis of hepatic cirrhosis. Br J Pharmacol. 2006 Aug;148(8):1144-55.
22. Cronstein BN. Adenosine receptors and wound healing. Scientific World Journal. 2004 Jan 16;4:1-8.
23. Chan ES, Fernandez P, Merchant AA, et al. Adenosine A2A receptors in diffuse dermal fibrosis: pathogenic role in human dermal fibroblasts and in a murine model of scleroderma. Arthritis Rheum. 2006 Aug;54(8):2632-42.